Halperin Scott A, Tapiero Bruce, Law Barbara, Diaz-Mitoma Francisco, Duval Bernard, Langley Joanne M, Elrick Donald B, Jacquet Jeanne-Marie
Clinical Trials Research Center, Dalhousie University and the IWK Health Centre, 5850/5980 University Avenue, Halifax, Nova Scotia, Canada B3K 6R8.
Vaccine. 2006 May 1;24(18):4017-23. doi: 10.1016/j.vaccine.2005.11.012. Epub 2005 Nov 21.
Since 1998, all children in Canada have been immunized with a pentavalent diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccine (DTaP-IPV-Hib) produced by one manufacturer (Pentacel). Recently, another DTaP-IPV-Hib (Infanrix-IPV-Hib) became available. Data on the interchangeability of these products was lacking.
In this multicentered, observer-blind study, healthy 15-20-month-old children previously immunized with three doses of Pentacel were randomly allocated to receive a single dose of Pentacel or Infanrix-IPV-Hib. Adverse events were documented by diary for 7 days post-immunization and unsolicited adverse events were documented for 30 days.
433 participants were enrolled (mean age 17.1 months). Rates of fever, anorexia and irritability were similar in both groups. Injection-site redness >20 mm (11.5% versus 5.6%; p = 0.038), injection-site pain (52.1% versus 39.4%; p = 0.009) and moderate or greater drowsiness (13.8% versus 7.4%; p = 0.042) were more common after Pentacel than Infanrix-IPV-Hib. The proportions of participants who were sero-protected or who sero-responded were similar for all antigens. Geometric mean titers or concentrations were similar for antibodies against diphtheria toxoid and poliovirus type 3. Geometric mean concentrations or titers were higher in the Infanrix-IPV-Hib group against pertussis toxin (88.5 EU/mL versus 65.6 EU/mL), filamentous hemagglutinin (207.3 EU/mL versus 132.1 EU/mL), pertactin (251.9 EU/mL versus 166.9 EU/mL) and poliovirus type 1 (1293.7 versus 976.2 reciprocal dilution). Geometric mean titers or concentrations were higher in the Pentacel group against H. influenzae type b (29 microg/mL versus 19 microg/mL), tetanus toxoid (5.6 IU/mL versus 4.7 IU/mL) and poliovirus type 2 (1437.3 versus 1134.2 reciprocal dilution).
A booster dose of Infanrix-IPV-Hib after three priming doses of Pentacel is well-tolerated and immunogenic in 15-20-month-old toddlers and can be used interchangeably.
自1998年以来,加拿大所有儿童均接种了由一家生产商(Pentacel)生产的五价白喉和破伤风类毒素、无细胞百日咳、灭活脊髓灰质炎病毒、b型流感嗜血杆菌结合疫苗(DTaP-IPV-Hib)。最近,另一种DTaP-IPV-Hib(Infanrix-IPV-Hib)上市。缺乏关于这些产品可互换性的数据。
在这项多中心、观察者盲法研究中,将先前接种过三剂Pentacel的15至20个月大健康儿童随机分配,分别接受一剂Pentacel或Infanrix-IPV-Hib。通过日记记录免疫接种后7天的不良事件,并记录30天内的非 solicited 不良事件。
共纳入433名参与者(平均年龄17.1个月)。两组的发热、厌食和易怒发生率相似。Pentacel接种后注射部位发红>20 mm(11.5%对5.6%;p = 0.038)、注射部位疼痛(52.1%对39.4%;p = 0.009)以及中度或更严重嗜睡(13.8%对7.4%;p = 0.042)比Infanrix-IPV-Hib更常见。所有抗原的血清保护或血清反应参与者比例相似。白喉类毒素和3型脊髓灰质炎病毒抗体的几何平均滴度或浓度相似。Infanrix-IPV-Hib组针对百日咳毒素(88.5 EU/mL对65.6 EU/mL)、丝状血凝素(207.3 EU/mL对132.1 EU/mL)、百日咳杆菌黏附素(251.9 EU/mL对166.9 EU/mL)和1型脊髓灰质炎病毒(1293.7对976.2倍稀释)的几何平均浓度或滴度更高。Pentacel组针对b型流感嗜血杆菌(29 μg/mL对19 μg/mL)、破伤风类毒素(5.6 IU/mL对4.7 IU/mL)和2型脊髓灰质炎病毒(1437.3对1134.2倍稀释)的几何平均滴度或浓度更高。
在15至20个月大的幼儿中,在三剂Pentacel基础免疫后接种一剂Infanrix-IPV-Hib耐受性良好且具有免疫原性,可互换使用。